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ORIGINAL ARTICLE
Lung ultrasound has limited diagnostic value in rare cystic lung diseases:
a cross-sectional study
Jesper Rømhild Davidsen a,b,c, Elisabeth Bendstrupd, Daniel P. Henriksen a,b, Ole Graumanne,f
and Christian B. Laursena,b,g
aDepartment of Respiratory Medicine, Odense University Hospital, Odense C, Denmark; bResearch Unit of Respiratory Medicine, Clinical
Institute, University of Southern Denmark, Odense C, Denmark; cSouth Danish Center for Interstitial Lung Diseases (SCILS), Odense
University Hospital, Odense C; dDepartment of Respiratory Medicine and Allergology, Aarhus University Hospital, Aarhus, Denmark;
eDepartment of Radiology, Odense University Hospital, Odense C, Denmark; fCenter of Clinical Ultrasound (CECLUS), Aarhus University,
Aarhus N, Denmark; gCenter for Thoracic Oncology, Odense University Hospital, Odense C, Denmark
ABSTRACT
Background: Lung ultrasound (LUS) used to identify interstitial syndrome (IS) and pleural
thickening related to diffuse parenchymal lung disease (DPLD) has shown significant correlations
with ground glass opacity (GGO) on high-resolution computed tomography (HRCT). However, the
applicability of LUS in patients with DPLD subtypes as rare cystic lung diseases has not previously
been investigated. This study aimed to observe if distinctive LUS findings could be found in
patients with lymphangioleiomyomatosis (LAM), pulmonary Langerhans cell histiocytosis (PLCH),
and Birt-Hogg-Dubé syndrome (BHDS).
Methods: This single centre case-based cross-sectional study of patients diagnosed with LAM,
PCLH and BHDS was conducted at a Danish DPLD specialist centre. Patients underwent clinical
examination including LUS. LUS findings were compared to findings scored according to a
modified Belmaati score on HRCT and reviewed in consensus between two pulmonologists and
one radiologist.
Results: Twelve patients with HRCT proven cystic lung disease were included, six with LAM, three
with PLCH, two with BHDS, and one with uncharacteristic cystic lung disease. The mean age was
48.7 years (SD ± 15.8). In general all had normal LUS findings. IS could not be found in any
patients despite GGO presentation on HRCT among 75% of the patients with a Belmaati in the
highest category of 0.76–1.00. Pleural thickening on LUS was present in three patients, but with
inconsistent findings.
Conclusion: This study indicates that LUS has limited value as a diagnostic tool in patients with
LAM, PLCH, and BHDS as normal LUS findings did not rule out severe cystic lung disease.
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Introduction
Lung ultrasound (LUS) has within the past 10 years
excelled as a fast and non-invasive examination mod-
ality to diagnose and monitor various conditions in the
lungs and pleura.[1,2] With LUS diseases, in which the
density of the lung interstitium is diffusely increased,
can be identified, by demonstration of multiple B-lines,
as the so-called interstitial syndrome (IS).[1,3] IS may
represent cardiogenic pulmonary oedema, ARDS,
interstitial pneumonias, but also presence of interstitial
inflammation and fibrosis in patients with diffuse par-
enchymal lung disease (DPLD).[1] Accordingly, LUS
used as a diagnostic tool to identify IS related to DPLD
has shown significant correlations with findings on
high-resolution computed tomography (HRCT) in
patients with different subtypes of DPLD, e.g. acute
eosinophilic pneumonia,[4] sarcoidosis, hypersensitiv-
ity pneumonitis, idiopathic pulmonary fibrosis,[5] and
patients with pulmonary manifestations secondary to
connective tissue diseases.[6–8]
Traditionally, disease progression and overall prog-
nosis in DPLDs is evaluated in conjunction with repeti-
tive HRCTs performed prior to clinical follow-ups.[9]
This may not only result in several inconvenient hospital
attendances but also an increased lifetime risk of cancer
development due to a cumulated radiation dose exposure.
[10,11] In contrast LUS excels by being a radiation-free
procedure that can be performed relatively rapidly in
relation to clinical attendance with minimal discomfort,
but also a procedure which is easy to assimilate.[12,13]
Consequently, LUS may be preferable to diagnose and
monitor DPLDs in some settings compared to HRCT.
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Lymphangioleiomyomatosis (LAM),[14–16] pul-
monary Langerhans cell histiocytosis (PLCH),[16] and
Birt-Hogg-Dubé syndrome (BHDS) [17] are rare
DPLDs. As in other DPLDs, a common feature of
LAM, PLCH, and BHDS is predomination of thin-
walled lung cysts causing an overall decreased lung
density.[18,19] As the pathoanatomical appearance of
these rare cystic lung diseases significantly differs from
other DPLDs the presence of B-lines and IS as
described in other DPLDs may thus not necessarily
be characteristic findings in the rare cystic lung dis-
eases. So far no studies have reported systematic use of
LUS in LAM, PLCH, and BHDS. Establishing knowl-
edge on potential characteristic LUS findings in these
cystic lung diseases or lack thereof is of significance in
order to select the most optimal diagnostic and disease
monitoring approach.[4–8]
The aim of this study was to observe whether dis-
tinctive LUS findings were present in patients with
LAM, PLCH and BHDS.
Materials and methods
Study design
This is a single centre case-based cross-sectional study
of patients diagnosed with LAM, PLCH, and BHDS.
Setting
In the Central and North Denmark Region, diagnosis
and management of DPLDs is accomplished at the
Western Danish Centre for Interstitial Lung Diseases
at Aarhus University Hospital. This centre receives
unselected patients suspected for DPLD from the
primary sector within the local area of Aarhus as
well as from all other hospital departments within
these regions, and thereby serves as a tertiary specia-
list centre covering an area of 1.85 million inhabi-
tants.[20] The study took place in 10 March 2015.
Study cohort
Patients were recruited at the Western Danish Centre
for Interstitial Lung Diseases. The diagnoses LAM,
PLCH, and BHDS were thus established by either of
the following:
a. a histological confirmation by bronchoscopy with
transbronchial lung biopsies or video assisted
surgical lung biopsy; or
b. on the basis of a conclusion from the multi-
disciplinary discussion (MDD) involving
pulmonologists, radiologists, pathologists, and
rheumatologists, in order to increase the diagnostic
precision.[21]
The project was approved by the Regional Ethics
Committee of Southern Denmark (Project ID
S-20140172), and the Danish Data Protection Agency
(14/41600), and was performed according to the
Declaration of Helsinki. All participants gave written
informed consent.
Procedure
Clinical examination
On a Pneumotrac model 6800 (Vitalograph, Ennis,
Ireland), all patients underwent a pulmonary function
test in accordance with the European Respiratory
Society (ERS) and American Thoracic Society (ATS)
standards including FEV1 (forced expiratory volume in
1 sec) and FVC in litres and per cent of predicted
(% pred.), and FEV1/FVC ratio.[22] Diffusion capacity
of the lung for carbon monoxide (DLCO) was singled
out from a previous follow-up less than six months
before the examination day. DLCO was measured as
a single-breath diffusion lung capacity.
LUS assessment
LUS was performed by two experienced physicians
(JRD and CBL), both EFSUMB certified in LUS.[23]
Patients were examined in a straight-backed sitting
position. The thorax was systematically scanned
according to anterior, lateral and posterior chest wall
using an adapted approach of the principles described
by Volpicelli and Lichtenstein,[1,3] and also used in
previous studies from this research group.[2,24] In a
vertical and horizontal direction, respectively, the ante-
rior chest wall was outlined from clavicles to dia-
phragm, and from sternum to anterior axillary line;
lateral chest wall from axilla to diaphragm, and from
anterior to posterior axillary line; posterior chest wall
from margo superior scapula to diaphragm, and from
posterior axillary to paravertebral line. The anterior
and lateral chest walls were divided into an upper
(zones 1 and 4); and lower zone (zones 2 and 3),
whereas the posterior chest wall was divided into an
upper, middle, and lower zone (zones 5–7) equivalent
to a total of seven zones for each hemithorax.[2,24] In
each zone the transducer was systematically placed
vertically across an intercostal space corresponding to
the centre of the specific zone. Supplementary horizon-
tal views of the intercostal space in a given zone were
performed in case of abnormal findings using the ver-
tical view. In all 14 scanning zones LUS was performed
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with a GE Logiq E9 (GE Healthcare, Milwaukee, WI,
USA) ultrasound system with a linear transducer using
a frequency of 6–15 MHz and with a depth and focus
setting of 4 cm and 1.5–2 cm, respectively.
Selected variables
LUS variables
B-lines are defined as vertical reverberation artefacts
originating from the pleural line extending uninterrupted
to the edge of the screen on the ultrasound machine
without fading (previously termed ‘comet-tails’).
The primary outcome variable was dichotomised
presence of IS. In accordance with the international
evidence based guideline for point-of-care LUS, IS
was defined as ≥3 B-lines in >2 anterior or lateral
zones on each hemithorax.[1]
Secondary outcome variables were dichotomised pre-
sence of the below-mentioned LUS findings obtained
from each individual scanning:
● lung sliding was defined as the dynamic move-
ment that can be observed when the parietal and
visceral pleura slide (pleural line) against each
other in synchrony with respiration.
● pleura thickness was defined as a thickened pleura
or thickened part of the pleural line seen a single
frame of the LUS clip.
● lung consolidation was defined as visible pathology
in the lung parenchyma. Visible lung consolidation
was further subdivided based on sonomorphologic
characteristics into e.g. pneumonia, embolism, and
tumour. Lung consolidations with uncharacteristic
sonomorphology were registered as ‘uncharacteris-
tic finding’.[2]
Findings such as visible pathology not related to the
visceral pleura or the lung parenchyma itself (e.g.
pleural effusion) was registered as ‘other findings’.
The LUS records for each patient were independently
reviewed by two pulmonologists. The final decision of
the specific LUS findings for each patient was achieved
when both agreed in the interpretation of the indivi-
dual LUS finding. In case of disagreement a radiologist
made the consensus decision using the same interpre-
tation approach as described above.
HRCT
The latest available HRCT prior to examination date
for each patient was evaluated and scored according to
a modified version of Belmaati et al.,[25,26] which
specifically aims to identify dichotomised presence of
findings as ground glass opacity (GGO), septal
thickening, peribronchial thickening, consolidation,
fibrosis, mosaic perfusion, air trapping and bronchiec-
tasis in central and peripheral parts of the right upper,
middle and lower lobes, and the left upper and lower
lobes corresponding to 10 areas in total.[25,26]
Presence/non-presence of a specific finding in each
area was scored with 1 and 0 respectively, and calcula-
tion of total score for each HRCT-finding was per-
formed by adding only the number of positive
findings (i.e. the number with score 1) divided with
the number of areas (i.e. 10). As an example patient
number 8 had presence of GGO in 8 of 10 areas
affecting an area with a score of 8/10 = 0.8. Thus, low
and high Belmaati scores represented no or high like-
lihoods, respectively, of presence of the specific radi-
ological finding. The modified Belmaati score for each
patient was obtained by three different physicians (OG,
CBL, JRD), who individually assessed each HRCT and
subsequently made a score based on consensus
principles.
Statistical analysis
The main outcomes were proportions of specific LUS
findings categorised to zones and proportions of specific
HRCT findings according to the modified Belmaati
score.
Continuous variables as baseline demographic data
were expressed, when appropriate, as mean(s) with
corresponding standard deviation (±SD), and descrip-
tive categorical data were expressed as proportions (e.g.
distribution of the different LUS-findings in which the
numerator represents the number of participants with
a positive specific LUS-finding and the denominator
the number of participants from the specific disease
category). All analyses were performed using Stata
Release 14.0 (StataCorp, College Station, TX, USA).
Results
Baseline findings
In total 12 patients with rare cystic lung diseases
accepted participation, of whom six were diagnosed
with LAM, three with PLCH, two with BHDS, and
one with uncharacteristic cystic lung disease. Six
patients had their diagnosis confirmed by biopsy. All
LAM patients were females and due to a positive gene
test two patients had tuberous sclerosis complex (TSC)
associated LAM. The two patients with BHDS were
men. The three patients with PLCH were or had been
smoking corresponding to 19 pack years (SD ± 15.5),
whereas none with BHDS and the majority of LAM
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patients (83.3%) had ever smoked. Patients were diag-
nosed on average 61.3 months (SD ± 49.2) prior to the
inclusion date, with LAM patients in general having the
longest disease duration. Individual baseline character-
istics are presented in Table 1.
BHDS patients and the patient with unclassified
cystic lung disease had normal ventilation and diffu-
sion parameters (Table 2). Patients with LAM and
PLCH exhibited a moderately reduced obstructive ven-
tilation and diffusion capacity.
LUS findings
Multiple B-lines equalling a number of ≥3 per zone were
found in three zones (2L, 3L, and 3R), corresponding to
three patients, but with such focal and multiple B-lines
in only one zone (Table 3). IS was not present in any of
the included patients.
Lung sliding was present in every zone on the
right hemithorax among all 12 patients, but in gen-
eral with a decreased presence of 91.7% on the left
hemithorax.
In three patients pleural thickening was found in
one zone, and observed only in the inferior lateral
zones (1 patient in zone 3L with LAM, and 2 patients
in zone 3R with LAM and PLCH respectively).
Lung consolidation was observed in two patients.
One had sonomorphologic characteristics of bilateral
pneumonia (zone 3L and 3R), and the other had
uncharacteristic findings not fulfilling sonomorpholo-
gic characteristics, i.e. pneumonia, atelectasis, tumour,
or pulmonary embolism.[1]
Table 1. Individual baseline characteristics.
Gender Age Extrapulmonary disease Pack VEGF-D
Patient (M/F) (years) Disease manifestation(s) Positive gene test Type of biopsy years (pg ml–1)
1 F 34 Unclass. – – – 18 471
2 F 44 PLCH – – VATS 26 –
3 M 49 BHDS Renal cysts + – – –
4 F 38 LAM TS, skin lipoma, angiomyolipoma + – – 846
5 F 76 LAM – – – – –
6 F 61 PLCH – – fTBB 43 –
7 M 46 BHDS Renal cysts + – – –
8 F 64 LAM – – VATS – > 4000
9 F 36 LAM – – Abdominal biopsy 5 > 4000
10 F 39 LAM – – VATS – 2512
11 F 71 LAM TS (genotype), angiomyolipoma + – – 2310
12 M 26 PLCH – – VATS 12 –
Abbreviations: – = none/not performed. M = male. F = female. LAM = lymphangioleiomyomatosis. PLCH = pulmonary Langerhans cell histiocytosis.
BHDS = Birt-Hogg-Dubé syndrome. Unclass. = unclassified cystic lung disease. fTBB = forceps transbronchial biopsy. VATS = video-assisted thoracoscopic
surgery. VEGF-D = vascular endothelial growth factor D. pg ml–1 = pictogram per millilitre.
Table 2. Baseline characteristics categorised according to disease entity.
Variable* LAM PLCH BHDS Unclassified All
N (%) 6 (50.0) 3 (25.0) 2 (16.7) 1 (8.3) 12 (100.0)
Gender (F:M) 6:0 2:1 0:2 1:0 9:3
Age (years) 54.0 ± 18.3 43.7 ± 17.5 47.5 ± 2.1 34.0 ± 0.0 48.7 ± 15.8
BMI (kg m–2) 23.3 ± 5.3 23.7 ± 2.5 24.5 ± 0.7 18.0 ± 0.0 23.2 ± 4.1
FEV1 (litres) 1.6 ± 1.1 1.9 ± 0.8 4.2 ± 0.5 3.3 ± 0.0 2.3 ± 1.3
FEV1 (% pred.) 56.8 ± 29.5 63.0 ± 24.3 97.0 ± 12.7 91.0 ± 0.0 67.9 ± 28.2
FVC (litres) 3.0 ± 1.4 3.4 ± 1.2 6.2 ± 0.3 4.7 ± 0.0 3.8 ± 1.6
FVC (% pred.) 92.3 ± 30.4 91.7 ± 12.4 113.5 ± 6.4 112.0 ± 0.0 97.3 ± 23.3
FEV1/FVC (%) 0.5 ± 0.2 0.6 ± 0.1 0.7 ± 0.1 0.7 ± 0.0 0.6 ± 02
TLC (litres) 5.0 ± 0.9 5.5 ± 1.5 8.8 ± 0.1 6.3 ± 0.0 6.0 ± 1.7
TLC (% pred.) 94.0 ± 13.3 98.0 ± 6.6 107.0 ± 2.8 104.0 ± 0.0 98.4 ± 10.4
RV (litres) 1.7 ± 0.3 2.0 ± 0.6 2.5 ± 0.1 1.7 ± 0.0 3.6 ± 5.7
RV (% pred.) 95.4 ± 8.7 115.3 ± 35.6 107.5 ± 0.7 99.0 ± 0.0 103.4 ± 19.1
DLCO (% pred.) 56.6 ± 10.4 54.0 ± 5.6 97.5 ± 7.8 77. ± 0.0 65.2 ± 18.8
KCO (% pred.) 62.2 ± 5.4 56.7 ± 4.9 92.0 ± 7.1 76.0 ± 0.0 67.4 ± 14.1
Smoking (%) Never 5 (83.3) 0 (0.0) 2 (100.0) 0 (0.0) 7 (58.3)
Former 0 (0.0) 2 (66.7) 0 (0.0) 0 (0.0) 2 (16.7)
Present 1 (16.7) 1 (33.3) 0 (0.0) 1 (100.0) 3 (25.0)
Disease duration# 84.7 ± 49.5 43.3 ± 62.0 4 ± 0.0 33 ± 0.0 61.3 ± 49.2
Abbreviations: M = male. F = female. SD = standard deviation. BMI = body mass index. FEV1 = forced expiratory volume in 1 sec. FVC = forced vital capacity.
TLC = total lung capacity. RV = residual volume. DLCO = diffusion capacity of the lung for carbon monoxide. KCO = carbon monoxide coefficient (diffusion
constant).
* Continuous data are expressed as mean ± standard deviation (SD); categorical data as number and percentage (%).
# Disease duration in months from time of diagnosis to study date.
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HRCT findings
HRCTs prior to individual examination date were per-
formed during 2005–2015 with a mean age of 43.8 (SD
± 43.0) months. In Figure 1 the mean Belmaati scores
are presented as proportions of the total for specific
HRCT findings according to the cystic lung diseases.
HRCT findings consistent with consolidation, mosaic
perfusion, bronchiectasis and septal thickening all
showed low scores coherent with no or almost no
observation of these findings. Air trapping was not
found in one third of the patients; however, as expira-
tion imaging had not been performed in eight (66.7%)
of the patients’ HRCTs, air trapping as a specific find-
ing could not be interpreted further. Half of the
patients had medium scores for peribronchial thicken-
ing, almost equally distribution between low and high
scores. High mean scores for GGO were present in
nine patients (75%) and in only two of the patients’
HRCTs (16.7%) were no GGOs observed.
Discussion
This is the first observational study to investigate the
applicability and diagnostic appropriateness of LUS in
a population of patients with cystic lung diseases. The
key findings are that IS and pleural thickening, which
are characteristic LUS findings in other subtypes of
DPLD,[4–8] either could not be found or had low
likelihood of presence in these patients with rare cystic
lung diseases. Despite severe cystic formation on
HRCTs we found normal LUS results, consisting of
normal lung sliding, normal pleural thickness and no
observation of IS (Figures 2 and 3).
LAM, PLCH and BHDS are rare DPLDs. The pre-
valence of LAM and PLCH is approximately 2–4 cases
per million,[14,27] but unknown for BHDS.[17] LAM
is seen almost exclusively in women with onset around
35 years of life and occurs in a sporadic form and with
association to tuberous sclerosis complex (TSC),
amongst whom 30–40% have affected lungs.[28] The
aetiology is unknown, but generally LAM presents by
an uncontrolled proliferation of smooth muscle and
epithelial like cells (LAM cells), resulting in progressive
cystic destruction of the lung parenchyma. LCH is
mainly seen in smokers, with an equal gender distribu-
tion in 20–40 year-olds, and is due to accumulation of
bone marrow derived monocytes (Langerhans’ cells) in
various tissues with both multiorgan involvement
(bone, skin, pituitary and lungs) and single site invol-
vement of the lungs.[27,29] Smoking is assumed to
activate and recruit Langerhans’ cells and other inflam-
matory cells, causing accumulation of Langerhans’ cellsTa
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in the lung parenchyma, inducing nodular inflamma-
tion which over time leads to cavitating and cystic
destruction.[27,29] In reverse, smoking cessation is
described to improve radiological findings compatible
with PLCH.[30] BHDS is an autosomal-dominant dis-
order caused by mutations in the gene encoding for the
Figure 1. HRCT specific findings categorised according to Belmaati [26] in pentiles in numbers and proportions in percentage of
total.
Figure 2. Patient #5 with LAM. (A) Transverse high-resolution computed tomography (HRCT) image of right and left upper and
central lobe areas according to Belmaati.[26] White arrow corresponds anatomically to LUS zone 1 in B. (B) LUS clip of right LUS
zone 1. White arrow indicates the pleural line.
Figure 3. Patient #8 with LAM. (A) Transverse high-resolution computed tomography (HRCT) image of right upper and middle
central and peripheral lobe areas and left upper central and peripheral lobe areas according to Belmaati.[26] White arrow
corresponds anatomically to right LUS zone 2 in B. (B) LUS clip of right LUS zone 2. White arrow indicates the pleural line.
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tumour suppressor protein folliculin (FLCN), which,
by poorly defined mechanisms, cause pulmonary
cysts, renal angiolipomas, and cutaneus lesions.[17]
Seventy-five per cent of the patients had diffuse
GGO appearance on their HRCTs. As GGO represents
diseases in which the alveolar spaces contain inflam-
mation, oedema, haemorrhage, or thickening of the
interstitium or alveolar walls, an a priori hypothesis is
that presence of IS and/or a higher number of B-lines is
due to an increased lung parenchymal density.
However, the HRCT-GGO findings in this study con-
tradict the LUS-IS findings. One possible explanation
for this GGO-IS disagreement is a possible time-bias,
since recently performed HRCTs were not available in
most patients. Still, as the one patient with the study
date HRCT also had general distribution of GGO,
another possible explanation of the GGO-IS disagree-
ment could be due to ”tissue compression” in the
remaining lung parenchyma in consequence of pro-
gressive evolving and expanding air filled cysts.
Overall, lung sliding was a normal finding in these
patients, however, one exemption was a single patient
with LAM who had previously left-sided pleurodesis
performed secondary to recurring pneumothorax. Due
to this procedure lung sliding was not present in all
scanning zones on the left hemithorax (Table 3).
Lung consolidation can be found in some types of
fibrotic DPLDs as a result of fibrotic atelectasis and
shrinkage, but in this study one patient showed signs of
consolidation compatible with an ongoing pneumonia
and one had an uncharacteristic finding, which did not
add further diagnostic value. The patient in whom LUS
identified pneumonic consolidation had clinical signs
compatible with pneumonia (fever, dyspnoea, sputum
production) and a subsequent chest X-ray revealed a
pneumonic infiltrate, which was absent on previous
chest X-rays.
Strength and limitations
Whether our results are representative cannot yet be fully
resolved since LUS has not been studied in cystic lung
diseases, and thus we have no direct frame of reference to
our results. Conversely, due to consensus on DPLD
management the patients were diagnosed and treated in
a tertiary specialist centre with access to MDD confer-
ences,[21,31] so there is good reason to believe that the
patients included actually suffered from rare cystic lung
diseases. The single centre set-up and small cohort
implies that the results cannot necessarily be applied to
other tertiary specialist centres. However, based on the
size of the centre from which our study cohort is
included and available epidemiological data on these
diseases,[14,17,27–29] a prevalence estimation of around
seven cases for each of the three cystic lung diseases in
focus was expected to be associated with this tertiary
specialist centre. Therefore, we find our sample rather
representative, which is furthermore supported by the
consistent baseline findings concerning gender and age
distribution and disease duration compared to existing
evidence (Table 1 and 2).[14,17,27,29]
We made no distinction between the subtypes of
cystic lung diseases in advance of LUS, so assessing
the results as one homogeneous disease category
might be a challenge. However, due to the low power
we were not able to analyse potential associations
between specific LUS findings and e.g. disease entity,
disease distribution, age, lung physiology, and genetic
disposition.
As only one of the 12 patients had a HRCT performed
on the study date while the remaining 11 patients had
their HRCTs performed during 2005–2015 a substantial
time-bias in comparing LUS with HRCT findings might
be present. In some patients the HRCT was a part of the
initial diagnostics in which a previous and more active
disease state including inflammation could very likely
have occurred with manifestation of GGO on HRCT,
and thus be the cause of the observed discrepancy
between LUS-IS and HRCT-GGO. However, the chronic
nature of these cystic lung diseases reduces the impact of
time bias, and it is unlikely that the results of the study
would have changed even if more recent HRCT exam-
inations were available.
Conclusion
The diagnostic value of LUS in patients with rare
cystic lung diseases such as LAM, PLCH, and BHDS
seems limited as normal LUS findings did not rule
out severe cystic lung disease. In a clinical setting
such knowledge, however, is important to be aware
of since LUS is not recommended as the first choice
of radiological imaging when aiming to diagnose
these diseases. Nevertheless, LUS may still be clini-
cally useful, since abnormal LUS findings should
alert the clinician of possible complications or con-
comitant disease.
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